PLX the path forward revolves around completing commercial development for their Fabry treatment without shareholder dilution.
3/18 Management said they had a cash runway through the end of 2019.
The Fabry Ph3 study will be read out mid-2019.
PLX has sought a vote to increase authorized shares by 28% at the next annual meeting during 5/18.
If a partner could be found for at least one of the two next treatments in their pipeline, dilution would almost definitely be avoided. The next treatments in their pipeline are for: 1) Ulcerative Colitis 2) CF
PLX may also be willing to take on debt to avoid dilution.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.